The expression of wt1 and bcl-2 is considered to have a proliferating and survival supporting effect in leukemia blast cells. Here we describe the use of siRNA against wt1 and bcl-2 in leukemic cell lines for successful growth inhibition. We have used two different sequences designated as siRNA-A and siRNA-B corresponding to positions within the wt1 coding sequence to downregulate wt1 and a commercially available siRNA kit to downregulate bcl-2. WT1 and bcl-2 gene expression in transfected leukemic cell lines were evaluated with RT-PCR and western blot analyses. MTT assay was used to measure the cell viability and flow cytometry using annexin V/PI-staining for apoptosis. K562 and HL-60 cell lines transfected with siRNA-A targeted to wt1 had greatly decreased levels of both wt1 mRNA and protein expression. In contrast, siRNA-B and control siRNA led almost to no effect on wt1 mRNA and protein expression. siRNA-A-reduced wt1 mRNA expression was associated with a decreased cell proliferation and increased number of apoptotic cells in K562 and HL-60 cells by 24 and 48 h after transfection. Combined treatment with wt1 siRNA and bcl-2 siRNA simultaneously was not able to override the cell growth and apoptosis effects compared to single treatment with wt1 siRNA. siRNAs targeted against human wt1 might be a valuable tool as antiproliferative agent against wt1 expressing leukemic cells.
Introduction
The Wilms' tumor gene (wt1) regulates the expression of different genes like the transforming growth factor b1, 1 human telomerase reverse transcriptase, 2 bcl-2, 3 vitamin D-receptor 4 and WT1 itself. 5 WT1 is located at the short arm of chromosome 11 and contains 10 exons. Exons 7-10 encode a member of the 'early growth response' family of Cys 2 -His 2 zinc finger transcription factors. 6 WT1 is overexpressed in various kinds of cancers like breast, 7, 8 lung, 9 colon, 10 thyroid cancer, 11 bone and soft-tissue sarcoma 12 and pancreatic ductal adenocarcinoma. 13 The acute myelocytic leukemia (AML) is an acute myeloproliferative disease characterized by maturation arrest within the myeloid lineage. In AML, wt1 is detected in the bone marrow of 70-80% of patients [14] [15] [16] and the expression is described with poor prognosis. [17] [18] [19] [20] Originally, wt1 was identified as a tumor-suppressor gene and the loss of function by mutation was responsible for the development of the Wilms' tumor, a childhood kidney neoplasm. It was reported previously as a high expression of wild-type wt1 in fresh leukemia cells, increased expression of wt1 at relapse in acute leukemia and growth inhibition of leukemic cells by wt1 antisense oligomers. 21 These results suggested that wt1 plays an important role in leukemogenesis and may have an oncogenic function rather than a tumor suppressor gene function in hematopoietic progenitor cells. WT1 protein is expressed coordinately with wt1 mRNA, supporting that wt1 is transcriptionally regulated. Yamagami et al. 22 reported that suppression of wt1 gene expression induced G 2 /M arrest in K562 cells accompanied with an increase of cell volume It was demonstrated that wt1 mRNA-specific hammerhead ribozymes decreased K562 proliferation and induced cell death correlating to the decrease in WT1 expression. 23 Additionally, wt1 expression is involved in chemotherapy resistance. In HL-60 and K562 cells, the wt1 expression correlates with the degree of vincristine resistance 24 but not with cisplatin or doxorubicin resistance in K562 cells.
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WT1 also regulates the antiapoptotic gene bcl-2, which might be involved in resistance to chemotherapy. 3 These data indicate the important function of wt1 for leukemic cell growth and survival and that the removal may have an antileukemic and chemotherapy-supporting effect. siRNA has become a powerful tool in molecular research. 26 In this report, we have investigated that the effect of siRNA-mediated silencing wt1 and bcl-2 alone or in combination on apoptosis and cell proliferation.
Materials and methods

siRNA design
siRNAs were synthesized by MWG, Ebersberg, Germany. siRNA sequences targeting wt1 (National Center for Biotechnology Information [NCBI] accession number AH003034) were synthesized. siRNA-A: ccauaccagugugacuuca corresponds to positions 9-27 of exon 7 within the wt1 coding sequence; siRNA-B: CCAUUCCAGUGUAAAACUU corresponds to positions 9-27 of exon 9 within the wt1 coding sequence. The wt1 siRNA sequences were subjected to BLASTN 2.2.9-program to avoid homologue human sequences of other genes. Bcl-2 siRNA (sc-29214) was obtained from Santa Cruz (CA, USA). Unspecific control siRNA was obtained from Santa Cruz (sc-37007). Cy3-labeled unspecific siRNA was purchased from Qiagen (Hilden, Germany).
Antibodies
Monoclonal anti-human WT1 (F-6), anti-a-tubulin (B-7) and goat anti-mouse secondary antibody for western blot were obtained from Santa Cruz Biotechnology, Inc. Anti-human BCL-2 clone 124 antibody was obtained from Dako A/S (Glostrup, Denmark).
Cell culture
The leukemic cell lines HL-60 (human promyeloid leukemia), K562 (human erythroid blast crisis of CML) and U937 (histiocytic lymphoma) were maintained in RPMI-1640, supplemented with 10% heat-inactivated fetal calf serum (FCS). All cell lines tested negative for mycoplasma using the PCRmycoplasma diagnostic-kit VenorGeM (Minerva Biolabs, Berlin, Germany). FCS was purchased from PAA Laboratories (Coelbe, Germany). RPMI-1640, phosphate-buffered saline (PBS), Opti-MEM I, Lipofectamine2000 (Invitrogen, Karlsruhe, Germany) and glutamine were obtained from Invitrogen (Karlsruhe, Germany).
In vitro transfection with siRNAs
The cells were transfected with siRNAs using the Lipofectamine2000 protocol. In brief, 1 day before transfection, cancer cells were seeded without antibiotics at 1 Â 10 5 cells/well in sixwell tissue culture plate (Becton Dickinson, San Diego, NJ, USA). The cells were transfected with siRNA at a concentration of 30 and 50 nM, respectively. The cells were incubated with siRNA plus Lipofectamine2000 in Opti-MEM I or in Opti-MEM I with Lipofectamine2000 (control cells) according to the manufacturer's protocol. Cells were incubated for 2 h in transfection medium. Cells were harvested 24 and 48 h after the beginning of the transfection for mRNA analysis, protein expression and flow cytometry. All transfections were performed in triplicate for each time point.
Efficiency of transfection
We have used Cy3-labeled unspecific siRNA (Qiagen, Hilden, Germany) to evaluate the efficiency of transfection. K562 and HL-60 cells were incubated over a period of 6 h. The number of Cy3-labeled cells was estimated with flow cytometry analysis.
RNA preparation and RT-PCR
Cells were harvested, centrifuged and washed with PBS. Total RNA was isolated with RNA-isolation mini kit and DNAse kit according to manufacturer's protocol (Versagene, Gentra Systems, Aberdeen, UK). All cDNA products were purchased from (ABgene, Surrey, UK), except Superscript II (Invitrogen, Karlsruhe, Germany). The cDNA was synthesized from 2 mg of total RNA and 1 ml (200 U) of Superscript II RT, 4 ml of 5 Â first strand buffer, 1 ml of anchored oligo-dT [15] [16] [17] [18] primer, 2 ml of DTT (0.1 mM), 1 ml of dNTP mix (10 mM) in 20 ml reaction volume. Reaction conditions were 421C 50 0 and 701C 10 0 . The following primers were used:
0 -CCTCGCCTTTGCCGATCC-3 0 , 626 bp. Two microliters of cDNA was subjected to PCR amplification in a Biometra Themocycler. PCR conditions were 5 ml 10 Â PCR buffer containing 3 ml MgCl 2 (1.5 mM), 1 ml dNTP (0.2 mM), 0.5 ml up and down primer (100 pM) and 0.3 ml Hot Start TaqPolymerase (ABgene) in 50 ml final volume. An initial cycle was performed at 951C for 15 min, following 30 cycles (b-actin, 25 cycles) of denaturation at 941C for 30 s, annealing at 601C for 40 s and extension at 721C for 1 min. The PCR products were visualized after electrophoresis with 1.5% agarose gel containing 1 ml ethidium bromide (1 mg/ml) per 100 ml agarose.
Western blot analysis
For western blot analysis, the cells were harvested in lysis buffer (0.05 M Tris-HCl, pH 8.0, 2% SDS). The viscosity was reduced by incubation with benzonase. The homogenate was centrifuged for 10 min at 14 000 g and the supernatant was taken for protein determination. Cell lysates (50 mg) were denatured in Laemmli buffer at 951C, and loaded on 10% sodium dodecyl sulfate (SDS) gel, separated at 100 V for 2 h and electrophoretically transferred to Hybond-C membrane (Amersham Pharmacia Biotech, Little Chalfont, UK). The membranes were incubated for 1 h in 5% powdered non-fat milk, 0.5% Tween-20 in PBS with monoclonal antibodies anti-WT1, anti-BCL-2 (1:250) and anti-a-tubulin (1:1000). The membranes were then incubated for 30 min in 5% powdered non-fat dry milk and 0.5% Tween-20 with goat anti-mouse serum (1:2000) . The bound antibody was detected by chemiluminescence using ECL reagents (Amersham Pharmacia Biotech).
Real-time RT-PCR
The following primers and probes were used.
abl:
WT1 and abl sequences were recently published. 27, 28 Amplification mixes (25 ml) contained 12.5 ml of 2 Â platinum Quantitative PCR Super Mix-UDG (Invitrogen), 7.5 pmol of each primer and 5 pmol of Taqman probe. Thermal cycling consisted of 2 min at 501C, 10 min at 951C, followed by 50 cycles at 951C for 15 s and 601C for 1 min. All tests were carried out in triplicate. The wt1 plasmid was kindly provided by J Trka (Charles University of Prague, Czech Republic).
Flow cytometric apoptosis assay
The percentage of apoptotic cells were determined on a FACSCalibur (BD, Heidelberg, Germany). The annexin V FACS analysis was performed according to the manufacturer's protocol (Annexin V Fluorescein in situ apoptosis detection kit; R&D Systems). Approximately 1 Â 10 5 cells/well were plated in six-well tissue culture plate (Becton Dickinson, NJ, USA). Cells were incubated with wt1 siRNA. Control cells were incubated with Lipofectamine2000 alone or treated with control siRNA. Cells were washed with PBS and resuspended in 100 ml annexin V/PI incubation buffer and incubated for 15 min at room temperature in the dark. 400 ml of 1 Â binding buffer was added to each sample and analyzed with flow cytometry.
Proliferation assay (MTT assay)
Cell viability was assessed by the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay (Sigma-Aldrich, Deisenhofen, Germany). Cells were incubated with 30 and 50 nM siRNA for 24, 48 and 72 h. All assays were performed in triplicate. MTT in PBS was added to each well to a final concentration of 0.5 mg/ml. After 4 h incubation dark-blue formazan was solubilized with 2000 ml isopropanole/0.04 N HCl. Absorbance was measured at 590 and 690 nm.
Statistics
All data are expressed as the mean7s.d. Difference between the treated and the control was analyzed by t-test. A probability of Po0.05 was considered significant.
Results
Transfection efficiency
The number of transfected cells within a population is of tremendous importance on gene-silencing experiments. In our experiments, we have used Cy3-labeled unspecific siRNA to estimate the number of transfected cells after a time of 6 h incubation. Apparently cell transfection using Lipofectamine2000 occurs within 2 h. In both cell lines (K562 and HL-60) the transformation plateaued at this point of time (Figure 1 SiRNA-mediated wt1 silencing W Glienke et al treatment with 50 nM siRNA. Similar results were found after 48 h (data not shown). Incubation with wt1 siRNA-B did not lead to any effect in all the three cell lines. In succession, the reduction of mRNA using siRNA-A resulted in a remarked decreased WT1 protein level after 48 h (Figure 3a) . The western blot analysis showed the inhibition of WT1 protein of K562 cells treated with 50 nM WT1 siRNA-A. The protein level was not influenced in both, control cells (no siRNA) and siRNA-B-treated cells. The reduction of mRNA using siRNA-A resulted in a remarked decreased BCL-2 protein level after 48 h (Figure 3) . The western blot analysis shows the inhibition of wt1 protein of K562 cells treated with 50 nM bcl-2. The protein level was not influenced in control cells (no siRNA) and control siRNA-treated K562 cells.
Real time RT-PCR quantification of wt1 transcripts after wt1 siRNA transformation
The downregulation of wt1 transcript was estimated with realtime RT-PCR. WT1 siRNA-A-treated HL-60 cells showed a significant reduction of wt1 transcripts after 24 h as compared to both, HL-60 control cells (no siRNA) and siRNA-B-treated HL-60 cells. The downregulation of wt1 achieved up to 48% (Figure 4a ).
Flow cytometric apoptosis assay
To evaluate whether the decrease in cell viability after siRNA treatment resulted from apoptosis, the amount of annexin V þ -cells were analyzed 24 h after treatment with siRNA-A. 
SiRNA-mediated wt1 silencing W Glienke et al
Compared to control cells, the treatment of HL-60 and K562 cells with siRNA-A showed a significant increase in apoptosis from 6.6% in control cells up to 12.2% in HL-60 and 9.2% in control cells up to 15.3% in K562 wt1 siRNA-transfected cells.
Combining of wt1 and bcl-2 siRNA
The downregulation of wt1 resulted in a decrease of cell viability as measured with MTT assay in HL-60 cells. wt1 siRNA of 30 nM reduced cell viability by about 20% and 50 nM about 28%. The use of 50 nM bcl-2 siRNA lead to a reduction of cell viability by about 12%. Combining both siRNA reduced the cell viability by about 18 (15 nM wt1 siRNA/15 nM bcl-2 siRNA) and 27% (25 nM wt1 siRNA/25 nM). We conclude that the expression of wt1 in these cell lines is a more important factor for cell survival. The downregulation of wt1 may have additional proapoptotic effects due to its central role in cellular signalling as described in the Introduction (Figures 5 and 6 ). In K562 cells, similar results were obtained (data not shown).
Discussion
Depending on the cell type, wt1 has either tumor-suppressing or tumor-promoting function. While wt1 expression in human prostate cancer cells induces apoptosis, 28 the expression of wt1 in leukemic cells has a proliferative supporting effect. Previous studies have shown that downregulation of wt1 expression by means of antisense oligonucleotides or ribozymes reduced cell viability and led to apoptosis. But, the downregulation of wt1 was achieved with high concentrations of antisense oligonucleotides. siRNAs have become a promising tool in molecular medicine. We could demonstrate the downregulation of wt1 in leukemic cell lines K562 and HL-60 with siRNA. HL-60 and K562 cell lines express wt1 at very high levels. A single incubation with siRNA-A showed a downregulation of wt1 mRNA expression in K562 and HL-60 cells as well as on protein level. Real-time RT-PCR quantification showed a downregulation of wt1 mRNA in HL-60 cells up to 48%. The cell lines HL-60 and K562 were responsive to the antiproliferative effects of wt1 siRNA in a dose-dependent manner, raising the possibility that wt1 siRNA silencing might be useful for the treatment of wt1 expressing leukemia cells in vivo.
Antisense oligonucleotides targeting bcl-2 are already in clinical trials. 29, 30 High expression of bcl-2 protein in AML is associated with poor response to chemotherapy. 31 The coexpression of wt1 and bcl-2 is predicted with poor survival in adult AML. 32 Both cell lines, HL-60 and K562 cells, express wt1 and bcl-2. The downregulation of bcl-2 resulted in a decreased cell viability. The combined downregulation of wt1 and bcl-2 simultaneously had an additive but not synergistic effect on cell viability. Similar results were obtained by Elmaagacli using wt1 and bcr-abl siRNA. 33 The benefit of using dual siRNA targets may overcome redundancy caused by simultaneous overexpression of multiple antiapoptotic genes in malignant cells. 34 But, as reported by Pandyra et al., simultaneous treatment of human cervical carcinoma (HeLa) and breast tumor (MCF-7) cell lines with siRNAs targeting thymidylate synthase (TS), an important gene in cellular proliferation and bcl-2, had unexpected, non-reciprocal antagonistic effects. Additionally, the treatment of HeLa cells with siRNA targeting bcl-2 resulted in increased TS mRNA and protein expression. 35 Pre-clinical data delivered promising results in combining bcl-2 targeting antisense oligonucleotides (ASO) (G3139, Genasense, Berkeley Heights, New Jersey, USA, Aventis/Genta) with cytotoxic chemotherapy in melanoma and prostate cancer. 36 Genasense is an 18-mer phosphorotioate oligonucleotide binding to the first six codons of the human bcl-2 mRNA. 37 Until now, the exact mechanism underlying the antitumor effect of Genasense is not fully understood. Besides downregulation of bcl-2, a non-antisense effect such as an immunostimulatory action through cytosine-phosphate-guanosine (CpG)-motifs SiRNA-mediated wt1 silencing W Glienke et al might contribute to the antitumor effect. This triggers severe immunostimulatory response mechanism-like recognition by toll-like receptor 9 (TLR9) in the plasmacytoid dendritic cells (pDC), B-cell production of interferons and activation of both, natural killer cells (NK) and CD4 þ /CD8 þ T cells. 38 In summary, our data support the ability of wt1 to suppress apoptosis in leukemia cells. The expression of wt1 seems to be more important for cell survival than expression of the antiapoptotic gene bcl-2. We therefore consider siRNA targeting human wt1 as possible tool against leukemic cells overexpressing wt1. The development of additional therapeutic options for AML/CML beyond chemotherapy is important in light of documented resistance to chemotherapy. 39 The use of siRNA against wt1 will have a chemotherapy supporting effect because inhibition of wt1 expression in vitro was associated with inhibition of imatinib-induced BCR-ABL tyrosine kinase activity. 40 Efforts have to be made for new technologies to deliver siRNA in a non-toxic way for therapeutic application. The highly specific function of siRNA to their target sequences will offer the possibility to inhibit different cancer-promoting genes like wt1 and bcl-2.
